Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has launched a Regulation A+ equity crowd-funding campaign. The announcement follows the qualification by the U.S. Securities and Exchange Commission of BRSF’s Form 1-A offering. The intended purpose of the offering is to provide both accredited and non-accredited potential investors an opportunity to support the company in its efforts to more fully introduce its proprietary technologies to the neurology market. Through its Reg A+ offering, Brain Scientific will sell units at $9 each, with a minimum investment of $500. The units are comprised of five shares of common stock and one warrant to purchase common stock, and investments can be made by check, ACH payments, wire transfer or major credit cards. The offering follows the launch of BRSF’s innovative NeuroCap, a disposable, pre-gelled, hospital-grade EEG headset that can be easily and quickly applied by almost any member of a clinical staff. “Our Regulation A+ offering will showcase our company to a much broader pool of potential investors, opening the door for additional growth opportunities to continue our work in providing needed solutions for optimal care and efficiency in neurology,” said Brain Scientific chairman Boris Goldstein in the press release. “With the wide-scale availability of NeuroCap, now is the time for Brain Scientific to attract new investors who support our mission to modernize the brain diagnostic market and bridge the gap in neurological care.”
To view the full press release, visit https://ibn.fm/SuKGZ
About Brain Scientific
Brain Scientific is a commercial-stage, health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information about the company, please visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork